« Back
Home /
Partner: Meridian |Hölzel Diagnostika

Meridian Life Science

Meridian Life Science, Inc. is a leading manufacturer of antibodies, viral antigens, recombinant proteins, PCR enzymes and nucleotides. For more than 40 years, the US company has been developing innovative life science solutions for daily laboratory needs. Our partner's primary focus is on improving diagnostic assay development by providing high quality products and services.

Meridian Life Science designs and manufactures a variety of immunoassay reagents, including blockers, antigens and antibodies. So-called cancer biomarkers serve as indicators for tumor development. They are particularly useful for making cancer easier to diagnose at an early stage. They are also useful in cancer diagnosis and treatment, potentially reducing cancer mortality rates. Meridian Life Science has a full line of markers for clinical and diagnostic use to identify breast, gynecological, gastrointestinal, blood and respiratory diseases.

The robust and mature quality system guarantees a consistently high quality of all products. The manufacture of reagents for molecular assays is certified according to ISO 13485: 2016. The production activities are documented according to cGMP guidelines. All processes are validated according to strictly defined protocols.

Cardiovascular diseases (CVD) are a major worldwide health problem, responsible for a third of all deaths. They generally refer to conditions in which blood vessels are narrowed or blocked, which can lead to heart attacks, chest pain (angina pectoris), or strokes. Meridian Life Science has a full line of markers for clinical and diagnostic use to identify various types of heart disease. Cardiac biomarker assays have proven particularly useful in providing rapid diagnosis and risk assessment in people with acute coronary syndrome (ACS). Heart markers are proteins, hormones, enzymes, or other substances that are expressed by myocardial cells and released into the circulating blood in cell necrosis. Several routinely used biomarkers include creatine kinase (CK), creatine kinase-MB (CK-MB), myoglobin, cardiac troponin T (cTnT), and cardiac troponin I (cTnI). So far, troponins have proven to be the most sensitive and specific indicators of heart injury. Other useful biomarkers are NT-proBNP, which can be used to predict an increased risk of recurring events after a cardiac arrhythmia. In general, the use of more than one biomarker increases the early predictive value compared to the use of a single marker, and advances in technology will increase the use of multi-marker profiles to improve and possibly individualize the treatment of CVD in the future. Our partner Meridian Life Science Inc. offers you an extensive product portfolio with numerous heart and metabolic markers for assay development.